Two Sigma Advisers
STML

Two Sigma Advisers’s Stemline Therapeutics, Inc. STML Stock Holding History

Two Sigma Advisers’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-22,300
Closed -$342K – 2485
2019
Q2 		$342K Sell
22,300
-31,100
-58% -$450K ﹤0.01% 1960
2019
Q1 		$686K Sell
53,400
-2,200
-4% -$24.9K ﹤0.01% 1673
2018
Q4 		$528K Sell
55,600
-45,300
-45% -$587K ﹤0.01% 1745
2018
Q3 		$1.68M Buy
100,900
+2,600
+3% +$41.7K ﹤0.01% 1310
2018
Q2 		$1.58M Buy
+98,300
New +$1.75M ﹤0.01% 1408

Other funds holding STML

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Two Sigma Advisers's STML Position: Q3 2019 in Review

Two Sigma Advisers sold out of Stemline Therapeutics, Inc. (STML) in Q3 2019, closing a stake of 22,300 shares — an estimated $342K sold.

Two Sigma Advisers first reported a position in STML in Q2 2018 and held it in 5 quarters. The position peaked at $1.68M in Q3 2018. 100 funds tracked by Wall St. Rank hold STML as of Q3 2019.

  • Two Sigma Advisers reported no remaining Stemline Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • Two Sigma Advisers sold 22,300 Stemline Therapeutics, Inc. shares in Q3 2019, an estimated $342K.
  • Two Sigma Advisers first reported a position in Stemline Therapeutics, Inc. in Q2 2018 and held it in 5 quarters.
  • Two Sigma Advisers's Stemline Therapeutics, Inc. position peaked at $1.68M in Q3 2018.
  • 100 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q3 2019.

Based on Two Sigma Advisers's 13F filing for Q3 2019, filed 14 Nov 2019.